Styrenix Q1FY27: consolidated PAT more than doubles YoY to ₹138 Cr as margins expand sharply
PAT +166.4% YoY · revenue +7.1% · margins expanding
₹1,010.86 Cr
+7.1% YoY
₹138.3 Cr
+166.4% YoY
13.64%
+8.2pp YoY
₹78.64
Styrenix's consolidated revenue for the quarter ended June 30, 2026 rose 7.1% YoY to ₹1,010.86 Cr (+22.4% QoQ), while PAT more than doubled YoY to ₹138.30 Cr, up from ₹51.92 Cr a year earlier and up 88.2% sequentially from ₹73.48 Cr in Q4 FY26. Consolidated EPS came in at ₹78.64 against ₹29.52 a year ago. The standalone entity posted PAT of ₹137.32 Cr (EPS ₹78.09), tracking closely with the consolidated figure, with the Thailand step-down subsidiary contributing ₹320.90 Cr of revenue and ₹5.03 Cr of PAT to the group. No exceptional items featured in either the current quarter or the year-ago quarter, so this is a clean like-for-like comparison rather than a base-effect artifact.
Q1 FY-2027 vs prior quarters
The growth sits almost entirely on the cost line rather than volumes or pricing — cost of materials consumed fell to 69.9% of consolidated revenue from 82.7% a year earlier, pushing PBDIT margin to 22.1% from 10.6% YoY (15.5% in Q4 FY26) and net margin to 13.7% from 5.5% YoY. Employee and other expenses grew broadly in line with revenue, so the margin expansion is squarely a raw-material spread story. That is notable against management's own May-2026 concall guidance, which flagged only that "raw material and finished product prices are expected to move in tandem" — language implying broadly stable spreads rather than the sharp widening actually delivered — so on this specific metric the quarter reads as a beat versus the company's own cautious framing.
The stock went into the print at ₹2,629.9, up 14.4% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Management anticipates continued pricing volatility in the short term due to ongoing supply chain disruptions, though raw material and finished product prices are expected to move in tandem. While specific volume and savings figures are difficult to predict, the company is on track with its ABS capacity expansion, expe
— This quarter: beat
Management gives no formal numeric guidance, and we found no analyst consensus estimates for this specific quarter — Styrenix is a thinly covered small-cap and no broker preview note turned up in search, so the print cannot be benchmarked against Street expectations. The ABS capacity expansion management flagged for H2 FY27 commissioning, and the longer-term plan to double ABS/SAN output in India while using Thailand as a capacity base (guided to turn attractive at 60-70% utilization), see no update in this filing. Alongside the results, the board declared an interim dividend of ₹23 per share (230% of face value), record date August 10, 2026 — a step-up in payout announced the same day as a June 2026 ITAT win deleting ₹17.11 Cr of additions, though that tax matter does not appear to have moved this quarter's effective tax rate, which held near 26.7% (26.5% standalone), consistent with a normal-course tax charge rather than a one-off credit.
W1
ABS capacity expansion commissioning progress toward the H2 FY27 timeline management flagged
W2
Durability of the raw-material cost ratio (69.9% of revenue this quarter vs 82.7% a year ago) — whether the spread normalizes or holds
W3
Thailand subsidiary utilization trajectory toward the 60-70% capacity level management said is needed for attractive returns
Record PAT Masks Volume Collapse; Margin Normalization Coming
Styrenix reported PAT surged 166% year-over-year, but a raw material–finished product pricing gap inflated earnings. Management was explicit: this is temporary. Strip it out and margins face material compression as the gap closes.
Styrenix reported consolidated PAT of ₹138.3 crore, up 166% year-over-year—the best bottom-line result in years. But here's the problem: management was explicit that this number is not one to extrapolate. Of the profit surge, the company disclosed that a gap between raw material costs and finished product pricing created abnormal gains. Management called it a 'snapshot in time' and 'not indicative of the sustainable business.' When that gap closes—which it will as input costs and selling prices normalize—margins will compress materially.
₹138.3 Cr
+166% YoY
~₹30–40 Cr
From RM–FP gap; transient
~₹100–110 Cr
At 10–12% historical NPM
38.9 KT
−26% YoY
The earnings quality problem: pricing, not operations
Consolidated EBITDA margin hit 22% (from ~20% prior year), and consolidated net profit margin reached 13.6%. But the driver is not operational leverage—it's a gap between where raw material costs spiked and where finished product pricing settled. Styrene monomer jumped to $1100–$1400 from $1000 pre-conflict; acrylonitrile to $1400–$1600 from $1200. Initial gaps between input cost inflation and output price increases benefited margins. Management explicitly stated that margins are 'not indicative of the sustainable business' and cautioned not to assume the expansion holds. When RM and FP pricing move in tandem (the normal state), expect reversion toward prior-year 10–12% net profit margins. That implies margin compression of 100–350 basis points from current levels—a material earnings drag in the second half.
The volume story: demand destruction, not pricing power
Standalone volume collapsed to 38.9 kilotonnes, down 26% year-over-year. This is the real number—and it contradicts any narrative about pricing power. In a normally functioning market, volume down 26% while prices are up suggests severe demand destruction, not disciplined supply management. Management confirmed the diagnosis: customers, particularly in the non-OEM (disorganized/unstructured) segment, became unwilling to buy material at higher prices. That segment saw 'far more exaggerated' impact (15–25% volume drop), while OEM (auto, appliances, organized) was more resilient but still hit. Consolidated volume was 50.8 kilotonnes, flat sequentially, which suggests destocking may have stabilized—but the 26% year-over-year deterioration is stark and shows the market is not absorbing production at these prices.
Strong EBITDA and PAT growth reflect operational resilience and disciplined execution.
PAT growth driven by raw material–finished product pricing gap, explicitly acknowledged as temporary. Margins 'not indicative of sustainable business' per management.
Overstated
Demand destruction due to pricing spikes; recovery expected once normalization occurs.
Standalone volume -26% YoY despite pricing uplift confirms demand destruction, but recovery timing uncertain. Management will not quantify when or how fast.
Partially answered
ABS expansion on track; capacity to continue absorbing volumes.
FY27 commissioning confirmed but no quarter specified. Brownfield complexity cited as reason for timeline vagueness.
Supported but vague
Thailand market building progressing; volumes flat but validations ongoing.
No commercial wins 1.5 years post-acquisition. Validations in 12–24 month cycle. 3-year frame for margin improvement is new and speculative.
Partial
What changed on this call: four implicit downgrades
Four material shifts emerged on this earnings call versus prior guidance: 1. Volume guidance collapsed. The company entered FY27 expecting mid-single-digit volume growth. Q1 delivered −26% in standalone—a miss of 30+ percentage points. 2. Margin outlook explicitly capped. Management rejected analyst hopes for higher post-expansion margins, explicitly guiding to assume normalization at prior-year levels (10–12% NPM). This signals management sees no structural margin expansion from ABS capex, despite higher-margin capacity coming online. 3. ABS capex timeline softening. Prior call implied 'H2 FY27' (Oct–Mar window). This call shifted to 'Q3–Q4 distinction is fairly precise' but safety and environmental priorities may push it. Brownfield complexity blamed; precision eroding. 4. Thailand recovery pushed out. Still flat 1.5 years post-acquisition with no commercial wins. 3-year margin improvement frame is new; prior calls implied sooner traction. Validations are in 12–24 month cycles with structural headwinds (energy, supply chain).
How the street is positioned
The market has already rendered a clear verdict. The stock fell −0.41% on day 1 post-announcement but accelerated lower, shedding 9.3% by day 3 and 10.37% by day 5—a sustained selloff. At ₹2,183.7 (as of 14-Aug-2026), the stock trades below both the 20-day and 50-day moving averages and 17.7% below its all-time high of ₹2,653. Technicals are deeply oversold (RSI 17.6), but that attracts bottom-fishers only if the fundamental story improves—which it hasn't. On ownership, Foreign Institutions have reduced their stake to 0.86% from 0.95% last quarter and 3.37% a year ago—a consistent withdrawal. Domestic Institutions hold steady at 17.44%. A bulk sale by Motilal Oswal Mutual Fund of 2.34 lakh shares at ₹1,884 (recorded 6 months prior) hints institutional conviction is low. The selloff is rational: earnings quality concerns (pricing-driven profit) combined with volume destruction and margin normalization risk justify caution. The oversold technicals are tempting, but they mask a deteriorating fundamental picture.
The bull-bear ledger
ABS capacity expansion (50k tonnes) on track for FY27; long-term capex cycle intact
Alternate sourcing activated and supply chain resilience demonstrated despite Middle East disruption
Transparent management communication; explicit on margin risks and unsustainability of current levels
Reported PAT inflated by transient pricing gap; unsustainable per management; margin compression inevitable
Standalone volume down 26% YoY despite pricing strength; demand destruction evident; recovery timing uncertain
ABS capex timeline vague and eroding (H2 → Q3–Q4 → open); brownfield delays raising execution credibility
Thailand stagnant 1.5 years post-acquisition; no commercial wins; 3-year margin recovery frame speculative
Risks, ranked by severity to a holder
Margin compression from pricing normalization
HighCurrent 13.6% NPM will revert to 10–12% historical range once raw material and finished product pricing move in tandem. That wipes out ₹27–32 crore of PAT—a 20–25% earnings hit. Q2 EBITDA margin will be the early signal.
Volume destruction persists; recovery timing unquantified
High26% volume decline despite pricing strength shows demand destruction, not supply constraints. Management won't quantify when recovery begins or how fast. If geopolitical volatility persists into H2, demand remains depressed through ABS commissioning.
ABS capex execution delays; brownfield complexity
MediumTimeline softened from H2 to Q3–Q4 to vague FY27 end. Safety and environmental priorities over precision. Any slip into Q1 FY28 pushes volume uplift benefit by 6 months, extending the pressure cycle through critical earnings recovery window.
Thailand underperformance and sunk capex risk
MediumFlat volumes 1.5 years post-acquisition; no commercial wins; validations in 12–24 month cycle. 3-year margin recovery frame is long and speculative. Risk of treating Thailand as write-off if competitive intensity (Chinese dumping cited) persists.
Geopolitical volatility and raw material price persistence
MediumStyrene monomer $1100–$1400 vs. $1000 pre-conflict; lead times +10–15 days from alternate suppliers; no clear exit timeline. Supply chain cost carries; margin pressure persists if volatility doesn't subside.
The debate
What to watch next
1 · Q2 EBITDA margin run-rate (coming next 4–6 weeks)
Management said current margins are 'snapshot in time.' If Q2 shows meaningful compression from pricing normalization (EBITDA margin back to 20–21% from 22%), it confirms the transient nature of this quarter and validates the margin headwind thesis. If margins hold elevated, the bear case weakens materially.
2 · ABS capex commissioning timing and quarter precision (H2 FY27, Oct–Mar 2027)
The goalposts have moved from 'H2 FY27' to 'Q3–Q4 likely' to vague 'FY27 end.' Any further delay or lack of month-level precision by early H2 is a red flag for execution risk. Commissioning in Q3 (Oct–Dec) unlocks volume uplift in time to offset margin pressure. Slip to Q4 or beyond (Jan–Mar) pushes recovery into FY28, extending the pressure cycle.
3 · Demand recovery signals in auto and appliances (H2 FY27, forward indicators)
Volume destruction was driven by non-OEM customer unwillingness to pay elevated prices, not structural demand decline. Watch for order book commentary, channel inventory fills, or end-consumer activity (auto production, appliance shipments) in H2. Early signals of pent-up demand materializing would validate the bull case. Radio silence through year-end extends the bear case.
Verdict
Styrenix delivered record profit this quarter, but it's built on borrowed time. The company is transparent about it, management is executing the long-term ABS capex story, and the market's 10%+ selloff from announcement is rational given earnings quality concerns. The stock remains a hold for existing shareholders—the dividend yield and long-term capacity story still matter, but near-term risks dominate. The oversold technicals (RSI 17.6) are tempting for new money, but the fundamental debate will not resolve until at least Q3 FY27. The single number to track from here is the Q2 EBITDA margin run-rate. If it compresses meaningfully (to <21%), the transient nature of this quarter is confirmed and margin headwinds are real. If it holds near 22%, the bull case gains credibility and the selloff becomes an opportunity. Expect earnings revision downside until that debate settles.
Record PAT masks volume collapse; margin normalization ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit consolidated PAT target (₹138.3 Cr exact) but through pricing, not volume. Standalone volume miss (-26%) offset by pricing uplift. ABS capex on track but timeline vague.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 PAT surged 166% YoY but driven entirely by a gap between raw material and finished product pricing—management explicitly called it temporary. Consolidated volume flat QoQ but standalone volume crashed 26% YoY. ABS capacity expansion (50k tonnes) on track for FY27 and is the long-term story; but near-term earnings will compress as pricing normalizes and demand remains uncertain. High macro risk.
₹1010.9 Cr
Revenue · +7.1% YoY₹138.3 Cr
Reported PAT · +166.4% YoYExpanding
Margins · vs guidance: OverstatedDid the claims hold up?
Demand destruction due to pricing spikes; recovery expected once normalization occurs.
MISSStandalone volumes fell 26% YoY despite pricing uplift; consolidated revenue 7.1% YoY despite mid-single-digit target at fiscal start.
Strong EBITDA and PAT growth reflect operational resilience and disciplined execution.
OVERSTATEDPAT +166% YoY driven by gap between raw material and finished product pricing (explicitly transient). Management stated margins are 'snapshot in time' and not sustainable.
ABS expansion on track; SAN merchant sales unaffected; capacity to continue absorbing volumes.
METABS expansion confirmed FY27 but no quarter specified. SAN sales (~15–20k tonnes/yr from ~100k capacity) confirmed to continue. No volume growth target articulated.
Non-OEM sector demand decline; OEM more resilient.
METManagement quantified non-OEM impact as 'far more exaggerated' but confirmed OEM also impacted. Volume recovery contingent on broad market normalization, not OEM resilience alone.
Thailand market building progressing; volumes flat but validations ongoing; margin improvement possible within 3 years.
PartialThailand sales flat for 1.5 years post-acquisition. Energy/supply chain constraints cited. 3-year frame for margin improvement is speculative; no commercial milestones achieved yet.
Earnings quality
What changed since the last call
Volume resilience guidance withdrawn
DowngradeEntered FY27 expecting mid-single-digit growth; Q1 saw 26% volume drop in standalone despite pricing uplift, showing demand destruction not pricing power.
Margin outlook downgraded (implicitly)
DowngradeManagement explicitly stated: current margins are 'not indicative of sustainable business' and not to assume expansion. Pricing gap is temporary; normalization will compress NPM from 13.6% toward prior-year levels.
Capex timeline guidance softened
NeutralABS expansion remains FY27 but no quarter specified (was 'H2 FY27' in prior calls; now 'Q3–Q4 distinction is fairly precise' but 'not in line with our priorities'—signaling delays possible).
Thailand recovery pushed out
DowngradeNo new commercial wins; validations still in 12–24 month cycle. 3-year frame for margin recovery is new; prior call implied sooner traction.
The Q&A
Moderate. Analysts pressed hard on margin sustainability (Aditya Khetan, SMIFS), volume recovery timing (Priyank Chheda, Vallum), capex delays (Ronak Chheda, Awriga), and Thailand stagnation (Krunal Shah, Enam). Management held defensive line: cited volatility, refused to quantify recovery, emphasized safety/brownfield complexity over precision. Did not concede margin risk explicitly but clearly tipped hand.
Demand destruction, non-OEM impact — Nirav Jimudia, Anvil Wealth
AnsweredUnwillingness to buy; non-OEM sector heavily impacted (15–25% segment-wide drop). OEM impact muted. Middle East disruptions drove pricing spikes, demand destruction not supply shortage.
Sustainable margin levels — Aditya Khetan, SMIFS
AnsweredCurrent margins a 'snapshot in time,' not indicative of sustainable business. Assume prior-year operational basis. Normalization expected once volatility subsides.
Thailand cost and volume stagnation — Aditya Khetan, SMIFS
DodgedNo cost increase stated; no guidance given on reduction timeline. Volumes will take time to pick up; current environment not conducive to timing prediction.
Demand catch-up in balance 9 months — Priyank Chheda, Vallum Capital
PartialSome inventory/channel stocking/destocking at play but not entire story. Overall pricing impact at multiple levels. Uncertain if catch-up will materialize; contingent on normalization.
Margin settlement level post-normalization — Priyank Chheda, Vallum Capital
AnsweredAssume normalization to same level, not higher. Volatility and uncertainty too high; unwilling to hazard guesses on margin expansion.
Raw material inventory and sourcing — Rahul Agarwal, IKIGAI Asset
AnsweredProduction in line with sales forecast. RM inventory slightly higher due to alternate sourcing (10–15 day longer lead times). Styrene monomer $1000→$1600–$1700→$1100–$1400 range; acrylonitrile $1200→$1800–$1900→$1400–$1600; butadiene $1000→$2500→current. Fully covered; lead times longer.
ABS capex timeline and SAN merchant sales impact — Rahul Agarwal, IKIGAI Asset
AnsweredSAN merchant sales will continue unaffected. Capacities expanded on all sites (rubber, SAN, compounding). No impact on merchant sales.
Pricing pass-through and gap — Deepak Poddar, Sapphire Capital
AnsweredYes, pricing gap (RM up more than finished product initially; then compressed) led to abnormal margins. Will not comment on current quarter but prior quarter pricing significantly higher than earlier quarter.
Auto sector demand, inventory strategies — Dhaval Shah, Girik Capital
AnsweredAuto production numbers more or less flat. Auto sector supplied accordingly. Impact muted vs. appliances. Tier 1 ancillaries buy directly from us; OE specifies product and share; smaller volumes via distributors.
Thailand demand and competitive intensity — Krunal Shah, Enam Asset Management
AnsweredOperating at low utilization on specific products. Demand impacted similarly to India. Competitive intensity high. Company not seeing huge volume impact for specific products. Structurally, scenarios similar across regions.
Market-building activity in Southeast Asia — Krunal Shah, Enam Asset Management
PartialActivity on track with good feedback but not translated to volume yet. Current environment difficult (demand reduction). Short-term phenomenon; structurally nothing changed.
Capex timeline and commissioning precision — Ronak Chheda, Awriga Capital Advisors
DodgedStill close to commissioning; brownfield complexity (running plant) makes precision difficult. Q3–Q4 distinction fairly precise but 'not in line with our priorities' (safety/env take precedence). Will happen this FY year.
STYROLOY and ASALAC volumes — Krunal Shah, Enam Asset Management
PartialFew hundred tonnes monthly. Don't break up products competitively but ~few thousand tonnes annualized.
SAN bifurcation and auto/non-auto mix targeting — Prerak Gandhi, Sowilo Investment Managers
PartialSell 15–20k tonnes SAN/yr from 100k capacity; mostly in-house. Auto, appliances, other sectors; split can vary depending on sector growth. Expect both sectors to grow in normalized environment; split to remain same if growth in line.
New business development from crisis — Ronak Chheda, Awriga Capital Advisors
AnsweredSupply chain disruptions don't trigger short-term customer switching; long spec process needed. No significant benefits from current crisis. Customers looking to expand supply for structural reasons; participating there.
Polystyrene expansion plans — Tushar Raghatate, Omega Portfolio Advisors
PartialBoth ABS and PS important; both have equal focus depending on customer requirements and capex allocation. ABS expansion prioritized now. PS expansion as business case becomes clear; will share in future.
Thailand 3-year margin recovery target — Tushar Raghatate, Omega Portfolio Advisors
PartialThailand cost structure higher than India; difficult to compare. As volumes improve over time, margin profile will strengthen. Target 3-year frame for improvement.
Thailand sales strategy, Chinese competition — Vidhi Shah, CNK UAE
AnsweredMigrated to own brand ~1.5 years ago (unknown in region). Sales to China, Japan, Vietnam, SE Asia, Korea. Strategy: more validations (12–24 month cycle), deployed sales teams in Shanghai, Vietnam, Seoul, Osaka. Differentiated product but high competitive intensity from China.
ABS expansion timing and volume guidance — Vidhi Shah, CNK UAE
DodgedFY27 completion confirmed but no specific quarter given (brownfield complexity, safety/env priorities). 8th, 9th, or 11th month not to be guessed. Volume guidance: don't give as company; production can sell most; geopolitical uncertainty prevents precision.
Guidance
No explicit FY27 revenue target given; mid-single-digit volume growth expected pre-war, now uncertain
LowQ1 saw revenue growth 6.6% (SA) and 7.1% (consol.) YoY but through pricing, not volume. Management won't project FY27 revenue due to geopolitical uncertainty.
Assume normalization to prior-year operational margin levels; no expansion expected
MediumCurrent NPM 13.6% inflated by pricing gap. Management explicitly: 'not indicative of sustainable business.' Expect compression as RM/FP pricing gap closes.
ABS expansion 50k tonnes to be commissioned in FY27 (Q3–Q4 most likely but no precision given)
MediumBrownfield expansion in running plant; safety/environmental priorities over timeline precision. Management confident in FY27 close but unwilling to name month.
Risks the call surfaced
Pricing volatility, geopolitical
HighMiddle East disruptions since March 2026 spiked RM costs (styrene monomer $1000→$1600–$1700; acrylonitrile $1200→$1800–$1900). Lead times 10–15 days longer from alternate suppliers. Volatility expected to persist; no clear stabilization timeline.
Volume destruction, demand sensitivity
HighQ1 saw 26% volume decline in standalone and 15–25% segment-wide decline due to customer 'unwillingness to buy at higher prices.' Non-OEM sector saw 'far more exaggerated' impact. Recovery contingent on normalization.
Margin compression
HighCurrent NPM 13.6% and OPM 21.8% inflated by gap between RM and finished product pricing (explicitly acknowledged as 'snapshot in time' by management). When gap closes (RM pricing and FP pricing move in tandem), margins will compress toward prior-year 10–12% range.
ABS capex execution, brownfield complexity
Medium50k-tonne ABS expansion is brownfield (in running plant). Safety, environmental compliance, and dynamic decisions prioritized over timeline precision. Q3 vs. Q4 distinction now being softened; no specific month given despite FY27 target.
Thailand recovery stagnation
MediumThailand volumes flat 1.5 years post-acquisition. Validations in 12–24 month cycle; no commercial wins yet. Energy constraints and supply chain disruptions in region adding headwinds. 3-year frame for margin improvement is speculative.
Management
Score 6/10. Transparent on headwinds (pricing gap, volume destruction, margin unsustainability). Refused to give precise guidance on capex/volume citing complexity and volatility. Honest tone but risk-avoidant on forward commitments. Hit consolidated PAT but through pricing arbitrage, not operational improvement. Standalone volume down 26% vs. implied mid-single-digit target at fiscal start. ABS capex on track (FY27) but brownfield delays evident.
1 · H2 FY27 (Q3–Q4)
ABS capacity expansion commissioning (50k tonnes); volume uplift flagged if market normalizes.
2 · Q2–Q3 FY27
Geopolitical stabilization + pricing normalization; demand recovery contingent on this.
3 · FY28–FY29
Thailand validations mature (12–24 month cycle); new customer additions expected if macro improves.
High macro risk.